Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes

BACKGROUND: Serum cancer antigen 19-9 (CA19-9) pro-vides additional information about mucinous cystic pancre-atic neoplasm (MPN). This study was undertaken to assess both CA19-9 and carcinoembryonic antigen (CEA) serum concentrations in consecutive patients affected by MPNs and other chronic benign and malignant pancreatic diseases. We also evaluated whether serum CA19-9 and CEA determina-tions provide additional information such as the presence of invasive carcinoma in MPN patients. METHODS: Serum CA19-9 and CEA from 91 patients with pancreatic diseases were tested by commercially available kits at the time of diagnosis. The upper reference limit of serum CA19-9 was 37 U/mL and that of serum CEA was 3 ng/mL. RESULTS: Thirty-ifve patients was diagnosed with chronic pancreatitis (CP), 32 with MPN, and 24 with pancreatic ductal adenocarcinoma (PDAC) conifrmed histologically. Surgery was carried out in 5 CP patients, in 10 MPN patients (7 of them had severe dysplasia), and 9 PDAC patients. Serum CA19-9 activity was high in 12 (34.3%) CP patients, in 7 (21.9%) MPN patients, and in 12 (50.0%) PDAC patients (P=0.089). High se-rum CEA concentrations were noted in 6 (17.1%) CP patients, in 6 (18.8%) MPN patients, and in 12 (50.0%) PDAC patients (P=0.010). In the 7 MPN patients associated with histological-ly conifrmed severe dysplasia, 3 (42.9%) patients had elevated serum activity of serum CA19-9, and 2 (28.6%) patients had high levels of CEA. CONCLUSION: Serum determination of oncological markers is not useful in selecting MPN patients with malignant changes.

Testing and assessing the performance of a new warm mix asphalt with SMC

Warm mix asphalt （WMA} is a new technology which asphalt mix is produced and placed at normal temperature. It has advantages including low cost, environmentally friendly, haul-convenience, and so on. WMA has been widely tested and applied in the USA in the last decade, but it has just started in China. Recently, a new WMA using a new plastic- macromolecule-normal temperature additive, which was called ＂SMC＂ by the production company, was introduced as asphalt modifier. Based on discussing the strength forming process of this new WMA with SMC, a series of laboratory tests, including Marshall stability test （MST）, boiling test （BT）, modified immersion Marshall test （MIMT）, freeze-thaw split- ring test （FTST）, rutting test （RT）, low-temperature bending test （LTBT）, and abrasion loss test （ALT）, were conducted in this study to assess the performance of this WMA and the capability of applying it on low volume roads in China. SMC modified asphalt mixed under normal temperature is used in testing samples. It was found that this WMA product exhibited merits on its strength, which was about 6.7 kN bigger than the requirement of 5.0 kN in the JTG F40-2004, on high-temperature stability, which is about 1100 times/ram greater than the requirement of 600-1000 times/mm in the ）TG F40-2004, and on its storage stability. Based on these indicators, it is recommended that this product could be used for low volume low class roads construction. However, due to the relatively lower water resistance and low-temperature cracking resistance, this product is suggested to be applied first in the areas with warm weather and little rainfall. In order to improve the perfor- mance of this WMA with SMC, further research on this SMC asphalt modifier should be continued.